Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

Video content above is prompted by the following:

• Could you highlight key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib in inoperable aRCC after ICI treatment and other relevant studies?
• What insights do real-world data and experience provide about sequencing strategies and the efficacy of TKIs after prior ICI therapy?
• Real-world outcomes with cabozantinib after prior ICI
• Are there any patients in which you consider immunotherapy rechallenge after progression on initial ICI-based therapy? How might you differentiate between rechallenging with PD-L1 inhibitors vs CTLA-4-based approaches?
• What insights do emerging data, such as the TiNivo-3 trial, provide regarding this strategy? Phase 3 TiNivo-2 trial investigating tivozanib ± nivolumab after an ICI